Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Tables)

v3.24.3
Note 3 - Revenue (Tables)
9 Months Ended
Sep. 30, 2024
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2024

   

2023

   

2024

   

2023

 

Pfizer (formerly Seagen)

  $     $ 9,179     $ 6     $ 14,088  

AstraZeneca

          3,909             8,399  

Servier

          3,951       47       3,846  

Genentech

                      12,697  

Boston Pharmaceuticals

          2,481             2,481  

Total Revenue

  $     $ 19,520     $ 53     $ 41,511  
Revenue From Contract With Customer, Milestone Payments [Table Text Block]
   

Research, Development, Regulatory & Commercial Milestones

   

Sales Milestones

 

Pfizer (formerly Seagen)

  $ 759     $ 450  

Boston Pharmaceuticals

    85       265  

Total potential milestone payments

  $ 844     $ 715